Skip to main content Skip to main navigation menu Skip to site footer

Pengaruh ekspresi Vascular Endothelial Growth Factors (VEGF) post-neoadjuvant kemoterapi terhadap respon kemoterapi (huvos), local recurrence, metastasis, dan survival pada pasien osteosarkoma


Background: Overexpression of VEGF before therapy has been associated with decreased survival and poor prognosis of osteosarcoma patients, but VEGF expression in osteosarcoma patients following receiving neoadjuvant chemotherapy has not been much elucidated. The purpose of this study was to determine the effect of VEGF expression after neoadjuvant chemotherapy on chemotherapy responses (HUVOS), local recurrence, metastases and survival of osteosarcoma patients.

Methods: A cross-sectional study was conducted in Jakarta during the 2009-2010 period to 19 osteosarcoma patients at Cipto Mangunkusumo Hospital, Jakarta. Data on patient’s characteristics, VEGF expression after chemotherapy, local recurrence, metastasis, chemotherapy response and survival in osteosarcoma patients were recorded and analysed using statistical analysis. All data were analysed using SPSS software version 16 for Windows.

Results: Most respondents were male (63.2%), age> 14 years (84.2%), stage IIB (94.7%), poor HUVOS (73.7%), size <10 cm (63, 2%), positive VEGF expression (57.9%), negative metastasis (73.7%), and death (73.7%). There was no significant relationship between VEGF expression and all parameters assessed (P> 0.05).

Conclusion: VEGF expression by living osteosarcoma cells after neoadjuvant chemotherapy is not significantly related to histological response (HUVOS), local recurrence and metastasis, but has a significant relationship with good survival.


  1. Salter R. Diagnosis of Disorders and Injuries of Musculoskeletal System. 3rd ed. Philadelphia: Lippincott-Williams-Wilkins 1999;14:400-403.
  2. Unni KK. Dahlin’s Bone Tumors. General Data on 11,087 Cases. 5th ed. Philadelphia: Lippincott-Raven Publishers, 1996:143-96.
  3. Perkumpulan Ahli Bedah Orthopaedi. Buku Besar Tumor Bagian Orthopaedi FKUI. Edisi 2. Jakarta. 2008
  4. Raymond AK, Ayala AG, Knuutila S et al. Conventional Osteosarcoma. World Health Organization Classification of Tumours of Soft Tissue and Bone. 1st ed. Lyon: IARC Press, 2002:264-85.
  5. Unni KK, Inwards CY, Bridge JA. Tumors of the Bones and Joints. 4th ed. Silver Spring: ARP Press, 2005:135-92.
  6. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: A Randomized, Prospective Trial of the addition of Ifosfamide and/or Muranyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate. J Clin Oncol. 2005;23(9):2004-11.
  7. Leung KS, Fung KP, Sher AHL, et al. Plasma Bone-Specific Alkaline Phosphatase as an Indicator of Osteoblastic Activity. J Bone Joint Surg. 1993;75(2):288-92.
  8. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. J Clin Oncol. 2002;20(3):776-90.
  9. Ward WG, Mikaelian K, Mirra JM et al. Pulmonary metastases of Stage IIB Extremity osteosarcoma and subsequent Pulmoonary metastases. J Clin Oncol. 1994;12(9):1849-58.
  10. Bacci G, Longhi A, Versari M, et al. Prognostic Factors for Osteosarcoma of the Extremity Treated by Neoadjuvant Chemotherapy: 15 years experience in 789 patients treated at a single institution. J Bone Joint Surg. 2006;106(5):1154-61.
  11. Kager L, Zoubek A, Pootschger U, et al. Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols. J Clin Oncol. 2003;21(10):2011-18.
  12. Wunder JS, Paulin G, Huvos AG, et al. The histological response to chemotherapy as a predictor of oncologic outcome of operative treatment of Ewing Sarcoma. J Bone Joint Surg Arm. 1998;80(7):1020-1033
  13. Unni KK. Osteosarcoma. In: Dahkin’s Bone Tumors: General Aspects and Data on 11087 Cases, Ed 5th. Philadelphia: Lippincott-Raven Publishers, 1996:143–184.
  14. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. 1980. Clin Orthop Relat Res. 2003;(415):4-18
  15. The JOA Musculo-Skeletal Tumor Committee. General Rules for Clinical and Pathological Studies on Malignant Bone Tumors, Ed. 2. Tokyo: Kanabara, 1990.
  16. Rosen G, Huvos AG, Marcove R, Nirenberg A. Telangiectatic osteogenic sarcoma. Improved survival with combination chemotherapy. Clin Orthop Relat Res. 1986;(207):164-73.
  17. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6(2):329-37.
  18. Bacci G1, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer. 1990;65(11):2539-53.
  19. Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis and therapeutic response in osteogenic sarcoma: the Memorial Hospital Experience. Cancer. 1992;69(3):698-708.
  20. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomized trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European osteosarcoma intergroup. Lancet. 1997;350(9082):911-7.
  21. Asai T, Ueda T, Itoh K, et al. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer. 1998;76(3):418-22.
  22. Mori S, Ueda T, Kuratsu S, et al. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP- 470 in murine osteosarcoma. Int J Cancer. 1995;61(1):148-52.
  23. Bettencourt MC, Bauer JJ, Sesterhenn IA, et al. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol. 1998;160(2):459-65.
  24. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77(5):858-63.
  25. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer. 1998;78(10):1379-84.
  26. Inoue K, Ozeki Y, Suganuma T, et al. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Cancer. 1997;79(2):206-13.
  27. Shindoh M, Higashino F, Kaya M, et al. Correlated expression of matrix metalloproteinases and ets family transcription factor E1A-F in invasive oral squamous-cell -carcinoma-derived cell lines. Am J Pathol. 1996;148(3):693-700.
  28. Lee YH, Tokunaga T, Oshika Y, et all, Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer. 1999;35(7):1089-93.
  29. Kaya M, Wada T, Akatsuka T, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000;6(2):572-7.
  30. Charity RM, Foukas AF, Deshmukh NS, et al. Vascular endothelial growth factor expression in osteosarcoma. Clin Orthop Relat Res. 2006;448:193-8.
  31. Zhou Q1, Zhu Y, Deng Z, et al. VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol. 2011;20(1):13-9
  32. Oda Y1, Yamamoto H, Tamiya S, et al. CXCR4 dan VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol. 2006;19(5):738-45.
  33. Kreuter M, Bieker R, Bielack SS, et al. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res. 2004;10(24):8531-7.
  34. Ek ET, Ojaimi J, Kitagawa Y, et al. Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? Int Semin Surg Oncol. 2006;3:7.
  35. Sznurkowska K, Lenckowski R, Popadiuk S, et all. Assessment of angiogenesis in children’s osteosarcoma. Med Wieku Rozwoj. 2006;10(3 Pt 1):737-44.
  36. Mizobuchi H, García-Castellano JM, Philip S, et al. Hypoxia Markers in Human Osteosarcoma An Exploratory Study. Clin Orthop Relat Res. 2008;466(9):2052-9.
  37. Mantadakis E, Kim G, Reisch J, et al. Lack of prognostic significance of Intratumoral angiogenesis in nonmetastatic osteosarcoma. J Pediatr Hematol Oncol. 2001;23(5):286-9.
  38. Chen W, He M, Aisner S, et all. Expression of cell cycle, angiogenesis and metastases associated factors in osteosarcoma - immunohistochemical analysis of tissue array in 35 patients. Journal of Clinical Oncology. 2007;25(18S):10036
  39. Jia SF, Guan H, Duan X, et al. VEGF did not enhance lung metastasis potential of human osteosarcoma cells. Proc Amer Assoc cancer Res. 2006;47:4330
  40. Huang Y, Lin Z, Zhuang J, Chen Y, Lin J, Prognostic significance of alpha V integrin and VEGF in osteosarcoma after chemotherapy, Onkologie; 2008;31(10):535-40
  41. Bajpai J, Sharman M, Sreenivas V, et al. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer. 2009;53(6):1035-9.
  42. Rossi B, Schinzari G, Maccauro G, et al. Neoadjuvant multidrug chemotherapy including High-Dose Methotrexate modifies VEGF expression in Osteosarcoma: an immunohistochemical analysis. BMC Musculoskelet Disord. 2010;11:34.

How to Cite

Dewi, K. A. C. (2019). Pengaruh ekspresi Vascular Endothelial Growth Factors (VEGF) post-neoadjuvant kemoterapi terhadap respon kemoterapi (huvos), local recurrence, metastasis, dan survival pada pasien osteosarkoma. Intisari Sains Medis, 10(3).




Search Panel

Kadek Ayu Candra Dewi
Google Scholar
ISM Journal